Compare CNTY & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNTY | MAIA |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 86.2M |
| IPO Year | 1996 | 2022 |
| Metric | CNTY | MAIA |
|---|---|---|
| Price | $1.50 | $1.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 73.0K | ★ 734.6K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | N/A |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.23 | $0.87 |
| 52 Week High | $2.85 | $3.19 |
| Indicator | CNTY | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 45.32 |
| Support Level | $1.48 | $1.26 |
| Resistance Level | $1.56 | $1.74 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 79.41 | 60.94 |
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has three reportable segments based on the geographical locations in which its casinos operate; United States; Century Casino & Hotel-Central City, and Century Casino & Hotel-Cripple Creek in Colorado, Mountaineer Casino, Racetrack & Resort in West Virginia, and Century Casino Caruthersville, and Century Casino Cape Girardeau in Missouri, Canada; Century Casino & Hotel, Century Casino St. Albert, Century Mile Racetrack in Edmonton and Casino Century Downs Racetrack and Casino in Calgary, and Poland; Casinos Poland.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.